首页> 中文期刊> 《罕少疾病杂志》 >醋酸泼尼松片在结核性多浆膜腔积液患者中的临床疗效及安全性研究

醋酸泼尼松片在结核性多浆膜腔积液患者中的临床疗效及安全性研究

             

摘要

目的:研究醋酸泼尼松片在结核性多浆膜腔积液患者中的临床治疗效果。方法选取2014年4月-2016年4月医院诊治的结核性多浆膜腔积液患者60例,根据患者治疗措施将患者分为对照组30例和观察组30例,对照组采用3HREZ/15HRE方案抗结核治疗,观察组在对照组基础上联合醋酸泼尼松片治疗。比较两组临床疗效。结果观察组治疗疗效率为93.3%,高于对照组的80.0%(P<0.05);观察组不良反应发生率为13.33%,显著低于对照组的30.00%(P<0.05)。结论与单一抗结核方案治疗相比,结核性多浆膜腔积液患者联合醋酸泼尼松片治疗效果理想值得推广应用。%Objective Evaluate the clinical treatment effect of prednisone acetate in tuberculous patients with more serous cavity effusion. Methods Select 60 tuberculous patients with more serous cavity effusion who diagnosis and treatment in our hospital from April 2014-April 2016. The 60 patients were divided into control group of 30 patients and observation group of 30 patients according to the different therapy. The control group adopts 3hrez/15hre plan anti-tuberculosis treatment, the observation group adopts therapy with prednisone acetate tablets on the basis of the control group. Results Compare clinical curative effect of the two groups, the observation group therapy efifcacy rate was 93.3%, higher than 80.0%in the control group (P<0.05) the incidence of adverse reactions in observation group was 13.33%, significantly less than 30.00% of the control group (P<0.05). Conclusion Tuberculous patients with more serous cavity effusion combined therapy with prednisone acetate tablets is more effective compared with single TB solution treatment, this treatment plan is worth popularization and application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号